Sovaprevir

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Sovaprevir
Sovaprevir.svg
Clinical data
Synonyms ACH-1625
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
NIAID ChemDB
Chemical and physical data
Formula C43H53N5O8S
Molar mass 799.98 g/mol
3D model (JSmol)

Sovaprevir (codenamed ACH-1625) is an experimental drug designed to treat the hepatitis C virus. It is under development by Achillion Pharmaceuticals. It acts as a NS3/4A inhibitor.[1]

Sovaprevir received Fast Track status from the U.S. Food and Drug Administration (FDA) in 2012.[2]

References[edit]

  1. ^ De Clercq, E (15 June 2014). "Current Race in the Development of DAAs (Direct-Acting Antivirals) Against HCV". Biochemical Pharmacology. 89 (4): 441–52. doi:10.1016/j.bcp.2014.04.005. PMID 24735613. 
  2. ^ Sovaprevir HCV NS3/4A Protease Inhibitor

External links[edit]